Zentalis Pharmaceuticals (ZNTL) News Today → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free ZNTL Stock Alerts $12.52 +0.09 (+0.72%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineResearch Analysts Issue Forecasts for Zentalis Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:ZNTL)marketbeat.com - May 9 at 7:33 AMZentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $32.00 Price Target at Stifel Nicolausamericanbankingnews.com - May 9 at 7:10 AMZentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $40.00 Price Target at HC Wainwrightamericanbankingnews.com - May 9 at 7:10 AMBuy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of Azenosertibmarkets.businessinsider.com - May 9 at 12:09 AMHC Wainwright Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $40.00marketbeat.com - May 8 at 4:01 PMZentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results, Beats Expectations By $0.91 EPSmarketbeat.com - May 8 at 8:41 AMPleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stockfinance.yahoo.com - May 8 at 8:11 AMZentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...finance.yahoo.com - May 7 at 10:10 PMZentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.72marketbeat.com - May 7 at 2:19 PMZentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progressglobenewswire.com - May 7 at 7:00 AMZentalis Pharmaceuticals, Inc. (ZNTL)ca.finance.yahoo.com - May 2 at 10:47 PMZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - May 1 at 5:30 PMZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 7.1%marketbeat.com - April 24 at 7:14 PMFederated Hermes Inc. Has $32.73 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)marketbeat.com - April 21 at 6:04 AMZentalis Pharmaceuticals CFO Melissa Epperly steps downinvesting.com - April 13 at 1:35 PMZentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rollingseekingalpha.com - April 12 at 8:15 PMZentalis Shares Fall After Chief Financial Officer Resignsmarketwatch.com - April 11 at 1:51 PMZentalis Pharmaceuticals Llc (ZNTL)investing.com - April 10 at 9:56 AMZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading 6.3% Higher marketbeat.com - April 9 at 12:11 PMVanguard Group Inc. Acquires 307,490 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)marketbeat.com - April 5 at 4:06 AMZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Up 7.1%marketbeat.com - April 3 at 4:52 PMZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 7.7%marketbeat.com - April 2 at 4:18 PMZentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024globenewswire.com - April 2 at 4:05 PMZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 1 at 5:30 PMZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Up 4.8%marketbeat.com - March 26 at 4:46 PMZentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Down 4.5%marketbeat.com - March 20 at 3:55 PMZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading 7.7% Higher marketbeat.com - March 12 at 1:24 PMZentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Down 11.5%marketbeat.com - March 11 at 3:17 PMAdage Capital Partners GP L.L.C. Has $6.05 Million Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)marketbeat.com - March 11 at 6:34 AMZNTL Jul 2024 12.500 callfinance.yahoo.com - March 11 at 1:15 AMZNTL Jul 2024 10.000 callfinance.yahoo.com - March 10 at 8:14 PMQube Research & Technologies Ltd Purchases Shares of 141,388 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)marketbeat.com - March 10 at 5:21 AMSectoral Asset Management Inc. Purchases 152,525 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)marketbeat.com - March 5 at 5:29 PMZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 1 at 6:00 PMLeerink Partnrs Weighs in on Zentalis Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:ZNTL)marketbeat.com - March 1 at 8:45 AMCharles Schwab Investment Management Inc. Has $8.87 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)marketbeat.com - March 1 at 4:26 AMZentalis Pharmaceuticals, Inc.edition.cnn.com - February 29 at 5:39 PMZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Expected to Earn Q2 2024 Earnings of ($0.91) Per Sharemarketbeat.com - February 29 at 8:22 AMBuy Rating on Zentalis Pharmaceuticals Amidst Undervalued Share Price and Promising Clinical Developmentsmarkets.businessinsider.com - February 29 at 7:38 AMZentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Intrinsic Value Is Potentially 98% Above Its Share Pricefinance.yahoo.com - February 29 at 7:38 AMBuy Rating Affirmed for Zentalis Pharmaceuticals on Strategic Positioning and Clinical Prospects in Ovarian Cancer Treatmentmarkets.businessinsider.com - February 28 at 4:34 PMOppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)markets.businessinsider.com - February 28 at 4:34 PMZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Up 11.3% After Analyst Upgrademarketbeat.com - February 28 at 11:27 AMZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - February 28 at 9:46 AMZentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $15.00 at Wedbushmarketbeat.com - February 28 at 8:30 AMZentalis Pharmaceuticals to Participate in Upcoming Investor Conferencesglobenewswire.com - February 28 at 7:00 AMTD Cowen Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)markets.businessinsider.com - February 28 at 12:31 AMZentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...finance.yahoo.com - February 27 at 7:31 PMZentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updatesglobenewswire.com - February 27 at 7:00 AMPrimecap Management Co. CA Has $20.74 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)marketbeat.com - February 26 at 8:48 AM Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made … Click here to see the presentation now. ZNTL Media Mentions By Week ZNTL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZNTL News Sentiment▼0.350.36▲Average Medical News Sentiment ZNTL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZNTL Articles This Week▼152▲ZNTL Articles Average Week Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CYRX News Today LBPH News Today ARQT News Today ETNB News Today ELVN News Today PRTC News Today TNGX News Today AUPH News Today OCUL News Today SAGE News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZNTL) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
